cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28130237
title: Endovascular therapy versus best medical care for acute ischemic stroke with distal medium vessel occlusion: a systematic review and meta-analysis

description: With the refinement of catheter technology, distal medium vessel occlusions (DMVOs) are now viewed as amenable to endovascular treatment (EVT) but its efficacy and safety remains unclear in AIS patients with DMVO. We conducted a systematic search of PubMed, Embase databases and Cochrane Library up to December 2023 using keywords to identify studies comparing EVT versus BMT in AIS with DMVOs. The assessed clinical outcomes were excellent functional outcome, good functional outcome, 90-day mortality, symptomatic intracranial hemorrhage (sICH), and early neurological improvement (ENI) after treatment. Overall, 31 studies were included. There were no significant differences in excellent functional outcome (OR: 1.21, 95% CI: 0.99-1.47), good functional outcome (OR: 1.03, 95% CI: 0.82-1.30) and 90-day mortality (OR: 1.17, 95% CI: 0.84-1.62). Additionally, EVT led to higher sICH (OR: 1.64, 95% CI: 1.09-2.47) and better ENI (OR: 1.50, 95% CI: 1.02-2.19) compared to BMT. In individuals with M2 occlusion receiving EVT showed better excellent functional outcomes (OR: 1.48, 95% CI: 1.07-2.03). Those patients with PCA occlusion showed no significant difference in functional outcomes. In individuals with ACA occlusion, EVT resulted in reduced functional independence (OR: 0.55, 95% CI: 0.31-0.98). For NIHSS &lt; 6, BMT achieved better functional independence compared to EVT (OR: 0.71, 95% CI: 0.51-0.98) and EVT showed higher sICH (OR: 3.44, 95% CI: 1.42-8.31). For patients with AIS and DMVO occlusion, EVT fails to improve functional prognosis while increasing sICH incidence. More randomized controlled trials are needed in the future to confirm these results.
DOI: 10.6084/m9.figshare.28130237.v1
title: Endovascular therapy versus best medical care for acute ischemic stroke with distal medium vessel occlusion: a systematic review and meta-analysis

description: With the refinement of catheter technology, distal medium vessel occlusions (DMVOs) are now viewed as amenable to endovascular treatment (EVT) but its efficacy and safety remains unclear in AIS patients with DMVO. We conducted a systematic search of PubMed, Embase databases and Cochrane Library up to December 2023 using keywords to identify studies comparing EVT versus BMT in AIS with DMVOs. The assessed clinical outcomes were excellent functional outcome, good functional outcome, 90-day mortality, symptomatic intracranial hemorrhage (sICH), and early neurological improvement (ENI) after treatment. Overall, 31 studies were included. There were no significant differences in excellent functional outcome (OR: 1.21, 95% CI: 0.99-1.47), good functional outcome (OR: 1.03, 95% CI: 0.82-1.30) and 90-day mortality (OR: 1.17, 95% CI: 0.84-1.62). Additionally, EVT led to higher sICH (OR: 1.64, 95% CI: 1.09-2.47) and better ENI (OR: 1.50, 95% CI: 1.02-2.19) compared to BMT. In individuals with M2 occlusion receiving EVT showed better excellent functional outcomes (OR: 1.48, 95% CI: 1.07-2.03). Those patients with PCA occlusion showed no significant difference in functional outcomes. In individuals with ACA occlusion, EVT resulted in reduced functional independence (OR: 0.55, 95% CI: 0.31-0.98). For NIHSS &lt; 6, BMT achieved better functional independence compared to EVT (OR: 0.71, 95% CI: 0.51-0.98) and EVT showed higher sICH (OR: 3.44, 95% CI: 1.42-8.31). For patients with AIS and DMVO occlusion, EVT fails to improve functional prognosis while increasing sICH incidence. More randomized controlled trials are needed in the future to confirm these results.
DOI: 10.6084/m9.figshare.28280891
title: Clinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials

description: Several randomized controlled trials (RCTs) have investigated the benefits of atrial fibrillation (AF) screening. However, since none have shown a significant reduction in stroke rates, the impact of screening on clinical outcomes remains uncertain. We conducted a systematic review and meta-analysis of RCTs reporting clinical outcomes of systematic AF screening in participants without known AF. Pooled risk ratios (RRs) were computed for all-cause stroke or systemic embolism, major bleeding, and all-cause mortality, comparing screening with no screening. Seven RCTs encompassing 76 458 participants were identified. One trial utilized implantable loop recorders for rhythm monitoring, while the others employed non-invasive screening methods. Pooled results indicated that AF screening was associated with a significant reduction in all-cause stroke or systemic embolism (RR 0.932, 95% CI 0.873–0.996, I<sup>2</sup> = 0%, <i>p</i> = 0.037), but had no effect on major bleeding (RR 0.996, 95% CI 0.935–1.060, I<sup>2</sup> = 0%, <i>p</i> = 0.876) or all-cause mortality (RR 0.987, 95% CI 0.945–1.031, I<sup>2</sup> = 0%, <i>p</i> = 0.550). We estimated a number needed to screen of 148 to prevent one stroke or systemic embolism over a 10-year period in a population of 75-year-olds. When only non-invasive screening methods were considered, the reduction in strokes was not statistically significant (RR 0.942, 95% CI 0.880–1.008, I<sup>2</sup> = 0%, <i>p</i> = 0.083). Systematic AF screening is associated with a modest yet statistically significant 7% relative reduction in stroke and systemic embolism, with no observed impact on major bleeding or all-cause mortality.
DOI: 10.6084/m9.figshare.28280891.v1
title: Clinical outcomes of atrial fibrillation screening: a meta-analysis of randomized controlled trials

description: Several randomized controlled trials (RCTs) have investigated the benefits of atrial fibrillation (AF) screening. However, since none have shown a significant reduction in stroke rates, the impact of screening on clinical outcomes remains uncertain. We conducted a systematic review and meta-analysis of RCTs reporting clinical outcomes of systematic AF screening in participants without known AF. Pooled risk ratios (RRs) were computed for all-cause stroke or systemic embolism, major bleeding, and all-cause mortality, comparing screening with no screening. Seven RCTs encompassing 76 458 participants were identified. One trial utilized implantable loop recorders for rhythm monitoring, while the others employed non-invasive screening methods. Pooled results indicated that AF screening was associated with a significant reduction in all-cause stroke or systemic embolism (RR 0.932, 95% CI 0.873–0.996, I<sup>2</sup> = 0%, <i>p</i> = 0.037), but had no effect on major bleeding (RR 0.996, 95% CI 0.935–1.060, I<sup>2</sup> = 0%, <i>p</i> = 0.876) or all-cause mortality (RR 0.987, 95% CI 0.945–1.031, I<sup>2</sup> = 0%, <i>p</i> = 0.550). We estimated a number needed to screen of 148 to prevent one stroke or systemic embolism over a 10-year period in a population of 75-year-olds. When only non-invasive screening methods were considered, the reduction in strokes was not statistically significant (RR 0.942, 95% CI 0.880–1.008, I<sup>2</sup> = 0%, <i>p</i> = 0.083). Systematic AF screening is associated with a modest yet statistically significant 7% relative reduction in stroke and systemic embolism, with no observed impact on major bleeding or all-cause mortality.
DOI: 10.6084/m9.figshare.30928031
title: Systemic inflammatory indexes as predictors of 18-month mortality among cirrhotic patients receiving transjugular intrahepatic portosystemic shunt

description: To investigate the relationship between inflammatory/nutritional indexes and 18-month mortality in cirrhotic patients undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure, and to develop a predictive nomogram. Lasso and stepwise multivariate Cox regression analyses were employed to identify prognostic determinants and construct a visual prognostic nomogram. Clinical data from 2017 to 2022 were utilized for model development, while data from 2023 were for validation. The performance of nomogram was assessed using the concordance index (C-index), the area under the curve (AUC), calibration curves, DeLong test, decision curve analysis (DCA), net reclassification improvement (NRI), integrated discrimination improvement (IDI) indexes, Kaplan–Meier curves, and the integrated Brier scores. We retrospectively included 249 patients for the development of nomogram and 66 for validation. Inflammatory indexes (systemic immune-inflammation index [SII], neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], lymphocyte-to-white blood cell ratio [LWR], neutrophil percentage-to-albumin ratio [NPAR], prognostic nutritional index [PNI]) were significantly correlated with mortality. Nomogram 1 incorporated the Child-Pugh score and SII, whereas Nomogram 2 included age, Child-Pugh, and SII. The C-index value for 18-month mortality were 0.79 and 0.82 for Nomogram 1 and Nomogram 2 respectively. The AUC for 6-, 12- and 18-month were 0.759, 0.829, 0.806 in Nomogram 1 and 0.782, 0.834 and 0.834 in Nomogram 2. Nomogram 2 was regarded as the final model for superior predictive performance. Calibration and DCA curves demonstrated its consistency and clinical utility. DeLong analysis confirmed statistical superiority of Nomogram 2 over Child-Pugh score alone. NRI and IDI analyses further supported the added prognostic value of SII. High-risk patients stratified by Nomogram 2 showed significantly reduced survival (<i>p</i> &lt; 0.001). We identified systemic inflammatory indexes as significant prognostic biomarkers for disease-specific mortality post-TIPS. A predictive nomogram was constructed and validated with strong discriminative efficacy for risk stratification of death.
DOI: 10.6084/m9.figshare.30928031.v1
title: Systemic inflammatory indexes as predictors of 18-month mortality among cirrhotic patients receiving transjugular intrahepatic portosystemic shunt

description: To investigate the relationship between inflammatory/nutritional indexes and 18-month mortality in cirrhotic patients undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure, and to develop a predictive nomogram. Lasso and stepwise multivariate Cox regression analyses were employed to identify prognostic determinants and construct a visual prognostic nomogram. Clinical data from 2017 to 2022 were utilized for model development, while data from 2023 were for validation. The performance of nomogram was assessed using the concordance index (C-index), the area under the curve (AUC), calibration curves, DeLong test, decision curve analysis (DCA), net reclassification improvement (NRI), integrated discrimination improvement (IDI) indexes, Kaplan–Meier curves, and the integrated Brier scores. We retrospectively included 249 patients for the development of nomogram and 66 for validation. Inflammatory indexes (systemic immune-inflammation index [SII], neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], lymphocyte-to-white blood cell ratio [LWR], neutrophil percentage-to-albumin ratio [NPAR], prognostic nutritional index [PNI]) were significantly correlated with mortality. Nomogram 1 incorporated the Child-Pugh score and SII, whereas Nomogram 2 included age, Child-Pugh, and SII. The C-index value for 18-month mortality were 0.79 and 0.82 for Nomogram 1 and Nomogram 2 respectively. The AUC for 6-, 12- and 18-month were 0.759, 0.829, 0.806 in Nomogram 1 and 0.782, 0.834 and 0.834 in Nomogram 2. Nomogram 2 was regarded as the final model for superior predictive performance. Calibration and DCA curves demonstrated its consistency and clinical utility. DeLong analysis confirmed statistical superiority of Nomogram 2 over Child-Pugh score alone. NRI and IDI analyses further supported the added prognostic value of SII. High-risk patients stratified by Nomogram 2 showed significantly reduced survival (<i>p</i> &lt; 0.001). We identified systemic inflammatory indexes as significant prognostic biomarkers for disease-specific mortality post-TIPS. A predictive nomogram was constructed and validated with strong discriminative efficacy for risk stratification of death.
DOI: 10.6084/m9.figshare.30444120
title: Anterior quadratus lumborum block at the lateral supra-arcuate ligament versus thoracic paravertebral block for postoperative analgesia after laparoscopic nephrectomy: a randomized non-inferiority trial

description: This study compared the analgesic effects of the anterior quadratus lumborum block at the lateral supra-arcuate ligament (QLB-LSAL) and thoracic paravertebral block (TPVB) for laparoscopic nephrectomy to verify whether the new quadratus lumborum block is an efficient technique for managing laparoscopic nephrectomy pain as an alternative to TPVB. This study was a prospective randomized noninferiority clinical trial. Before general anaesthesia, 80 participating patients were randomly allocated to receive QLB-LSAL (20 mL of 0.5% ropivacaine) or TPVB (20 mL of 0.5% ropivacaine). The primary outcome was the mean visual analogue scale (VAS) score in the first 24-hafter surgery. The secondary outcomes included the cutaneous sensory block area, intraoperative haemodynamic changes, consumption of sufentanil at 24-h postoperatively, and postoperative recovery data. The mean VAS score during the first 24-h was 1.92 ± 0.28 in the QLB-LSAL group and 1.79 ± 0.25 in the TPVB group. The mean treatment difference (QLB-LSAL–TPVB) in the primary outcome was 0.13 (95% CI 0.02 to 0.25). The upper limit of the 95% CI remained below the non-inferiority margin. After 10 and 30 min, the TPVB group had significantly greater cutaneous sensory block area (<i>p</i> &lt; 0.001). The consumption of sufentanil at 24-h postoperatively was similar between the two groups (<i>p</i> &gt; 0.05). Neither intraoperative hemodynamic alterations nor postoperative recovery metrics showed significant differences between the two groups (<i>p</i> &gt; 0.05). At 24-h postoperatively, QLB-LSAL had analgesic effects that were not inferior to those of TPVB for patients undergoing laparoscopic nephrectomy. Chinese Clinical Trial Registry website; registration number: ChiCTR2100048226.
DOI: 10.6084/m9.figshare.30444120.v1
title: Anterior quadratus lumborum block at the lateral supra-arcuate ligament versus thoracic paravertebral block for postoperative analgesia after laparoscopic nephrectomy: a randomized non-inferiority trial

description: This study compared the analgesic effects of the anterior quadratus lumborum block at the lateral supra-arcuate ligament (QLB-LSAL) and thoracic paravertebral block (TPVB) for laparoscopic nephrectomy to verify whether the new quadratus lumborum block is an efficient technique for managing laparoscopic nephrectomy pain as an alternative to TPVB. This study was a prospective randomized noninferiority clinical trial. Before general anaesthesia, 80 participating patients were randomly allocated to receive QLB-LSAL (20 mL of 0.5% ropivacaine) or TPVB (20 mL of 0.5% ropivacaine). The primary outcome was the mean visual analogue scale (VAS) score in the first 24-hafter surgery. The secondary outcomes included the cutaneous sensory block area, intraoperative haemodynamic changes, consumption of sufentanil at 24-h postoperatively, and postoperative recovery data. The mean VAS score during the first 24-h was 1.92 ± 0.28 in the QLB-LSAL group and 1.79 ± 0.25 in the TPVB group. The mean treatment difference (QLB-LSAL–TPVB) in the primary outcome was 0.13 (95% CI 0.02 to 0.25). The upper limit of the 95% CI remained below the non-inferiority margin. After 10 and 30 min, the TPVB group had significantly greater cutaneous sensory block area (<i>p</i> &lt; 0.001). The consumption of sufentanil at 24-h postoperatively was similar between the two groups (<i>p</i> &gt; 0.05). Neither intraoperative hemodynamic alterations nor postoperative recovery metrics showed significant differences between the two groups (<i>p</i> &gt; 0.05). At 24-h postoperatively, QLB-LSAL had analgesic effects that were not inferior to those of TPVB for patients undergoing laparoscopic nephrectomy. Chinese Clinical Trial Registry website; registration number: ChiCTR2100048226.
DOI: 10.6084/m9.figshare.28130291
title: Using network pharmacology and molecular docking technology, proteomics and experiments were used to verify the effect of Yigu decoction (YGD) on the expression of key genes in osteoporotic mice

description: Yigu decoction (YGD) is a traditional Chinese medicine prescription for the treatment of osteoporosis, although many clinical studies have confirmed its anti-OP effect, but the specific mechanism is still not completely clear. In this study, through the methods of network pharmacology and molecular docking, the material basis and action target of YGD in preventing and treating OP were analyzed, and the potential target and mechanism of YGD in preventing and treating OP were clarified by TMT quantitative protein and experiment. Network pharmacology and molecular docking revealed that the active components of YGD were mainly stigmasterol and flavonoids. Molecular docking mainly studied the strong binding ability of stigmasterol to the target. Animal proteomics verified the related mechanism of YGD in preventing and treating OP. Based on the KEGG enrichment of network pharmacology and histology, our animal experiments <i>in vivo</i> verified that YGD may play a role in the treatment of OP by mediating hif1- α/vegf/glut1 signal pathway. YGD prevention and treatment of OP may be achieved by interfering with multiple targets. This study confirmed that it may promote osteoblast proliferation and protect osteoblast function by up-regulating the expression of proteins related to HIF signal pathway.
DOI: 10.6084/m9.figshare.28130291.v1
title: Using network pharmacology and molecular docking technology, proteomics and experiments were used to verify the effect of Yigu decoction (YGD) on the expression of key genes in osteoporotic mice

description: Yigu decoction (YGD) is a traditional Chinese medicine prescription for the treatment of osteoporosis, although many clinical studies have confirmed its anti-OP effect, but the specific mechanism is still not completely clear. In this study, through the methods of network pharmacology and molecular docking, the material basis and action target of YGD in preventing and treating OP were analyzed, and the potential target and mechanism of YGD in preventing and treating OP were clarified by TMT quantitative protein and experiment. Network pharmacology and molecular docking revealed that the active components of YGD were mainly stigmasterol and flavonoids. Molecular docking mainly studied the strong binding ability of stigmasterol to the target. Animal proteomics verified the related mechanism of YGD in preventing and treating OP. Based on the KEGG enrichment of network pharmacology and histology, our animal experiments <i>in vivo</i> verified that YGD may play a role in the treatment of OP by mediating hif1- α/vegf/glut1 signal pathway. YGD prevention and treatment of OP may be achieved by interfering with multiple targets. This study confirmed that it may promote osteoblast proliferation and protect osteoblast function by up-regulating the expression of proteins related to HIF signal pathway.
DOI: 10.6084/m9.figshare.29416660
title: Diagnostic accuracy of history taking, physical examination, and auxiliary examination for thumb osteoarthritis: a systematic review

description: To conduct a systematic review to evaluate the diagnostic accuracy of history taking, physical examination, and auxiliary examination for thumb osteoarthritis (OA). MEDLINE ALL, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, and CINAHL were searched up to October 2023. Studies focused on patients with hand or thumb pain suspected of thumb OA, considering any diagnostic methods as the index test, with any diagnostic assessment of thumb OA as the reference standard were included. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were extracted. QUADAS and GRADE were applied to assess the evidence. Seven studies were included. History taking (two studies, 1096 participants) showed very low certainty of evidence;physical examination (five studies, 427 participants) revealed moderate certainty of evidence; auxiliary examinations (one study, 20 participants) indicated low certainty of evidence. History taking showed sensitivity of 47% to 100%, specificity of 40% to 63%, and accuracy of 40% to 80%. Physical examination demonstrated sensitivity of 2% to 100%, specificity of 75% to 100%, and accuracy of 47% to 98%. Auxiliary examination exhibited sensitivity of 72%, specificity of 86%, and accuracy of 76%. The adduction test, extension test, and metacarpal pressure-shear tests were reported to have accuracy above 90% based on two studies. Based on few studies, the diagnostic accuracy of history taking and physical examination for thumb OA varied across studies, while knowledge about auxiliary examination was limited. The adduction test, extension test, and metacarpal pressure-shear test are recommended for thumb OA diagnosis.
DOI: 10.6084/m9.figshare.29416660.v1
title: Diagnostic accuracy of history taking, physical examination, and auxiliary examination for thumb osteoarthritis: a systematic review

description: To conduct a systematic review to evaluate the diagnostic accuracy of history taking, physical examination, and auxiliary examination for thumb osteoarthritis (OA). MEDLINE ALL, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, and CINAHL were searched up to October 2023. Studies focused on patients with hand or thumb pain suspected of thumb OA, considering any diagnostic methods as the index test, with any diagnostic assessment of thumb OA as the reference standard were included. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were extracted. QUADAS and GRADE were applied to assess the evidence. Seven studies were included. History taking (two studies, 1096 participants) showed very low certainty of evidence;physical examination (five studies, 427 participants) revealed moderate certainty of evidence; auxiliary examinations (one study, 20 participants) indicated low certainty of evidence. History taking showed sensitivity of 47% to 100%, specificity of 40% to 63%, and accuracy of 40% to 80%. Physical examination demonstrated sensitivity of 2% to 100%, specificity of 75% to 100%, and accuracy of 47% to 98%. Auxiliary examination exhibited sensitivity of 72%, specificity of 86%, and accuracy of 76%. The adduction test, extension test, and metacarpal pressure-shear tests were reported to have accuracy above 90% based on two studies. Based on few studies, the diagnostic accuracy of history taking and physical examination for thumb OA varied across studies, while knowledge about auxiliary examination was limited. The adduction test, extension test, and metacarpal pressure-shear test are recommended for thumb OA diagnosis.